Protagenic Therapeutics Appoints Bill Nichols Jr. as President
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Protagenic Therapeutics announced the appointment of Bill Nichols Jr. as President. At Protagenic, Nichols will drive integrated clinical development, corporate strategy, and enterprise planning as the Company prepares to initiate Phase 2 enrollment for PT00114 in 2026.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
